Global Genital Warts Treatment Market to Surpass US$ 2,253.6 Million by 2028, Says Coherent Market Insights (CMI)


SEATTLE, July 22, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global genital warts treatment market is estimated to be valued at US$ 1,628.9 million in 2021 and is expected to exhibit a CAGR of 4.7% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Genital Warts Treatment Market:

Key players operating in the market are focusing inorganic strategies such as mergers and acquisitions for the development of drugs, which is expected to offer a lucrative opportunity for the market players to launch their novel products in the market. For instance, in April 2019, Aresus Pharma GmbH (Aresus), a German pharmaceutical company, acquired rights for Veregen, a drug for the treatment of genital warts, from Medigene.

In October 2018, Novan entered into partnership with Health Decisions, a specialist Contract Research Organization (CRO), and announced clinical trial Phase II data for the treatment of external genital warts (EGW).

Request for sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4534

Key Market Takeaways:

The global genital warts treatment market is expected to exhibit a CAGR of 4.7% over the forecast period, owing to increasing product launches by key players. For instance, in July 2014, Paladin Labs Inc., a subsidiary of Endo International plc., a pharmaceutical company announced the launch of Veregen (sinecatechins) Ointment, 10%, a topical treatment for external genital and perianal warts (condylomata acuminata) in immunocompetent patients aged 18 years and older.

Moreover, the increasing prevalence of genital warts is expected to drive the market growth over the forecast period. For instance, in January 2019, according to a report published in Springer nature, a study was conducted on 1020 women, where the mean age of study participants was 38 years, and 56% of the participants were reported to be HIV-negative while 44% were found to be HIV-positive. In the same study, the prevalence of genital warts was reported to be 1% among HIV-negative women and 5% among HIV-positive women.

Competitive Landscape:

Key players operating in the global genital warts treatment market include Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee's Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4534

Market Segmentation:

  • Global Genital Warts Treatment Market, By Drug Type:
    • Imiquimod
    • Podophyllin and Podofilox
    • Trichloroacetic Acid
    • Sinecatechins
    • Others
  • Global Genital Warts Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Genital Warts Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

Anosmia Market, by Type (Idiopathic Anosmia and Congenital Anosmia), by Treatment (Therapies (Nasal Endoscopy and Imaging) and Medications (Decongestants, Antihistamines, and Steroid Nasal Sprays)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read more: https://www.coherentmarketinsights.com/market-insight/anosmia-market-4334

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Read more: https://www.coherentmarketinsights.com/market-insight/human-papillomavirus-hpv-and-cytomegalovirus-cmv-therapeutics-market-2707

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedInTwitter

 

Contact Data